Discovery/R&D
-
Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D.
10/11/2023
On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.
-
Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.
8/21/2025
On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.
-
BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko
3/5/2023
Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final episode in our special series recorded at JPM Week in San Francisco. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression technology designed to address common cell therapy administration challenges and unwanted, off-target immungenicity effects. Ko also shares progress on the company's ex-vivo candidate EXG-34217, an autologous cell therapy for telomere biology disorders, offers his take on the ever-crowded RNA therapeutics space and how the company is separating itself from the crowd, and much more!
-
Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.
11/15/2021
Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space \_and\_ the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity.
-
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
11/5/2026
On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients.
-
Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed
1/23/2023
Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery efforts, which have yielded a wide range of multi-modal candidates spanning a range of cancer indications. Our discussion digs into the company's transition from R&D to the clinic, how its built an uncommonly comfortable cash position through partnership, and its ambition to become a fully-integrated commercial-stage biotech.
-
BoB@JPM: Support Of A Blossoming Pipeline With Sangamo's Sandy Macrae, Ph.D.
2/5/2023
The Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Conference. This week's episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph.D., who rationalizes the company's aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California. Dr. Macrae zeroes in on the relationship between people and processes that's enabled the company to grow to more than 500 associates working on nearly 20 cell therapy, gene therapy, and genome engineering programs.
-
High-Throughput Discovery With BIOPTIC's Andrey Dobry
1/19/2025
Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and advanced screening are reshaping drug discovery. Learn more about BIOPTIC’s bold vision, the challenges of data access, and overcoming skepticism in the biotech industry.
-
Modernizing Clinical Trial Operations With Merck's Jennifer Sheller
12/18/2025
On this episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for conducting trials in over 60 countries.
-
Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.
7/23/2025
On this week's Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology.